IOBT

IO Biotech, Inc. (NASDAQ:IOBT) is a clinical-stage biopharmaceutical company founded in 2014 and based in Copenhagen, Denmark. The company went public in November 2021 and focuses on developing innovative immune-modulating cancer therapies using its proprietary T-win technology platform. As a clinical-stage company, IO Biotech is currently advancing multiple product candidates through various phases of clinical trials, with its lead programs targeting some of the most challenging forms of cancer including melanoma, lung, head and neck, and bladder cancers.